FH: physicians will try ‘whatever is available’
This article was originally published in Scrip
Executive Summary
Physicians treating patients with familial hypercholesterolemia will certainly be keen to try out both or either of the two novel compounds that have just run the gauntlet of the US FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC; scripintelligence.com, 17 October 2012 and 18 October 2012), assuming that the agency follows the majorities in the advisory groups and approves the drugs.